Blockbuster therapy allows early-stage lung cancer patients to "survive without cancer" longer, and it has been launched in China

▎Editor of WuXi AppTec's content team On March 22, Genentech, a subsidiary of Roche, announced that its PD-L1 antibody Tecentriq (atezolizumab, atezolizumab) is in the treatment of early stage non-small cell lung cancer NSCLC) patients reached the primary endpoint in a phase 3 clinical trial.

In the NSCLC patient group in stage II-IIIA, compared with the best supportive care (BSC), the patient's disease-free survival (DFS, survival without disease recurrence) is significantly improved.

The press release pointed out that this is the first phase 3 clinical trial to show that in patients with early resectable lung cancer, cancer immunotherapy can improve disease-free survival compared with the best supportive treatment.

 Lung cancer is one of the leading causes of cancer deaths in the world, and NSCLC accounts for 80-85% of all lung cancers.

Today, about half of patients with early-stage lung cancer will still relapse after surgical removal of the tumor.

Treating lung cancer early before it spreads may help prevent cancer from recurring and provide people with the best chance of curing lung cancer.

 Tecentriq is an anti-PD-L1 monoclonal antibody that binds to the PD-L1 protein on the surface of tumor cells and tumor infiltrating immune cells.
It can not only block the binding of PD-L1 to PD-1 receptors, but also prevent PD -L1 and B7.
1 receptor binding.

By inhibiting PD-L1, Tecentriq can activate T cells of the human immune system to attack tumor cells.

Tecentriq has been approved to treat 5 indications in the United States.

In China, Tecentriq (atelizumab, trade name: Taishengqi) has been approved for combination chemotherapy, the first-line treatment of extensive-stage small cell lung cancer; and the combination with bevacizumab for the treatment of hepatocellular carcinoma.

In a randomized, multi-center, open-label phase 3 clinical study named IMpower010, NSCLC patients in stage IB-IIIA were surgically removed and treated with cisplatin, and then randomly received Tecentriq or the best supportive treatment.

The test results showed that Tecentriq, as an adjuvant treatment after surgery and chemotherapy, significantly improved the DFS of patients with stage II-IIIA NSCLC, and the degree of DFS benefit was particularly obvious among PD-L1 positive people.

 "These landmark results show that Tecentriq may become the first cancer immunotherapy to help patients with resectable early-stage lung cancer extend their lives and prevent cancer recurrence," said Dr.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
We are excited about the clinical benefits that Tecentriq may bring to lung cancer patients, especially the PD-L1 positive patient population.

We will submit these data to the regulatory agency as soon as possible.

"Reference: [1] Pivotal Phase III Study Shows Genentech's Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning.
Retrieved March 22, 2021, from Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.

If you need guidance on treatment plans, please go to a regular hospital for treatment.